Your browser doesn't support javascript.
loading
Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.
Eberlein, Catherine A; Stetson, Daniel; Markovets, Aleksandra A; Al-Kadhimi, Katherine J; Lai, Zhongwu; Fisher, Paul R; Meador, Catherine B; Spitzler, Paula; Ichihara, Eiki; Ross, Sarah J; Ahdesmaki, Miika J; Ahmed, Ambar; Ratcliffe, Laura E; O'Brien, Elizabeth L Christey; Barnes, Claire H; Brown, Henry; Smith, Paul D; Dry, Jonathan R; Beran, Garry; Thress, Kenneth S; Dougherty, Brian; Pao, William; Cross, Darren A E.
Afiliación
  • Eberlein CA; AstraZeneca Oncology Innovative Medicines, Alderley Park, Macclesfield, Cheshire, United Kingdom.
  • Stetson D; AstraZeneca Oncology Innovative Medicines, Gatehouse Park, Waltham, Massachusetts.
  • Markovets AA; AstraZeneca Oncology Innovative Medicines, Gatehouse Park, Waltham, Massachusetts.
  • Al-Kadhimi KJ; AstraZeneca Oncology Innovative Medicines, Alderley Park, Macclesfield, Cheshire, United Kingdom.
  • Lai Z; AstraZeneca Oncology Innovative Medicines, Gatehouse Park, Waltham, Massachusetts.
  • Fisher PR; AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom.
  • Meador CB; Department of Medicine and Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee.
  • Spitzler P; Department of Medicine and Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee.
  • Ichihara E; Department of Medicine and Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee.
  • Ross SJ; AstraZeneca Oncology Innovative Medicines, Alderley Park, Macclesfield, Cheshire, United Kingdom.
  • Ahdesmaki MJ; AstraZeneca Oncology Innovative Medicines, Alderley Park, Macclesfield, Cheshire, United Kingdom.
  • Ahmed A; AstraZeneca Oncology Innovative Medicines, Gatehouse Park, Waltham, Massachusetts.
  • Ratcliffe LE; AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom.
  • O'Brien EL; AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom.
  • Barnes CH; AstraZeneca Oncology Innovative Medicines, Alderley Park, Macclesfield, Cheshire, United Kingdom.
  • Brown H; AstraZeneca Oncology Innovative Medicines, Alderley Park, Macclesfield, Cheshire, United Kingdom.
  • Smith PD; AstraZeneca Oncology Innovative Medicines, Alderley Park, Macclesfield, Cheshire, United Kingdom.
  • Dry JR; AstraZeneca Oncology Innovative Medicines, Gatehouse Park, Waltham, Massachusetts.
  • Beran G; AstraZeneca Oncology Innovative Medicines, Alderley Park, Macclesfield, Cheshire, United Kingdom.
  • Thress KS; AstraZeneca Oncology Innovative Medicines, Gatehouse Park, Waltham, Massachusetts.
  • Dougherty B; AstraZeneca Oncology Innovative Medicines, Gatehouse Park, Waltham, Massachusetts.
  • Pao W; Department of Medicine and Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee.
  • Cross DA; AstraZeneca Oncology Innovative Medicines, Alderley Park, Macclesfield, Cheshire, United Kingdom. Darren.Cross@astrazeneca.com.
Cancer Res ; 75(12): 2489-500, 2015 Jun 15.
Article en En | MEDLINE | ID: mdl-25870145
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Acrilamidas / Receptores ErbB / Compuestos de Anilina Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Animals / Humans Idioma: En Revista: Cancer Res Año: 2015 Tipo del documento: Article País de afiliación: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Acrilamidas / Receptores ErbB / Compuestos de Anilina Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Animals / Humans Idioma: En Revista: Cancer Res Año: 2015 Tipo del documento: Article País de afiliación: Reino Unido